Real-World Innovation Pioneering chemical Discovery with Generative AI

“The collaboration with AgPlenus has accelerated the identification of a class of herbicide chemistry that targets a new mode-of-action for weed control, something the industry has been lacking for decades."

“Bringing together AgPlenus’ expertise with Bayer’s CropKey approach to crop protection innovation will help accelerate the delivery of essential, sustainable, and affordable solutions to farmers and set a new benchmark in the industry.”

“This EUREKA-funded collaboration marks a pivotal step for Systasy in extending our PathwayProfiler platform to neutrophil biology. Partnering with Evogene’s AI innovation, LMU’s clinical expertise, and Weizmann’s validation strengths positions us to deliver breakthrough therapies addressing unmet needs in hyper-inflammatory diseases. Our hyper-multiplexed, patient-derived assays will provide the high-quality functional data essential for accelerating discovery and ensuring translational success.”

“We are thrilled to partner with Evogene to design an optimized new therapeutic candidates to promote remyelination for MS and other neurodegenerative disorders. The synergistic combination of Evogene’s Chempass-AI platform and generative chemistry together with Unravel’s patient RNA-derived Living Molecular Twins™ demonstrates the acceleration of drug development driven by novel data and advanced algorithms since patients cannot wait.”

“We are excited to join forces with Evogene in this groundbreaking endeavor. For more than a decade, our research has revealed for the first time how small metabolites can self-assemble into amyloid-like structures that contribute to the pathology of numerous rare and common diseases. By integrating our fundamental understanding of molecular self-assembly with Evogene’s cutting-edge AI-driven drug design platform, we have a unique opportunity to develop novel therapeutics that specifically target these pathological processes and ultimately improve treatment for patients.”